# S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

> **NCT01809691** · PHASE3 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 1313 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** TAK-700
- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT01809691
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-08
- **Primary completion:** 2022-03-08
- **Final completion:** 2025-09-09
- **Target enrollment:** 1313 (ACTUAL)
- **Last updated:** 2025-12-31

## Collaborators

- Millennium Pharmaceuticals, Inc.
- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01809691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01809691, "S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01809691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*